SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Graybug Vision, Inc. (Nasdaq – GRAY)

BALA CYNWYD – December 6, 2022 /Newsfile/ – Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Graybug Vision, Inc. (“Graybug” or the “Company”) (Nasdaq – GRAY) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the Company’s agreement to merge with CalciMedica Inc. (“CalciMedica”). Under the terms of the agreement in the all-stock transaction, Graybug equity holders are expected to collectively own approximately 29% of the combined company, and pre-merger CalciMedica equity holders are expected to collectively own approximately 71% of the combined company.

The investigation concerns whether the Graybug Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution to Graybug shareholders in the combined company.

If you own shares of Graybug stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, Two Bala Plaza, Suite 805, Bala Cynwyd, PA 19004, or call toll free 855-576-4847.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.